HLA-DRB1 and myeloid sarcoma: We re-analysed the risk carried from HLA class II variants, and specifically determined by both DRB1* and DQB1* alleles (DRB1*- DQB1* haplotype) in a Sardinian MS family sample more than twice as large as in our previous study [24].